Cellegy and PanGeo sign Tostrex deal

23 August 2001

Cellegy Pharmaceuticals and PanGeo Pharma have entered into an agreementunder which the latter will make the former's Tostrex (testosterone gel), developed for the treatment of hypogonadism, at its Montreal, Canada, manufacturing facility, reports the Montreal Gazette.

PanGeo will supply certain minimum quantities of Tostrex, which is currently in Phase III clinical trials, over a five-year period after final US Food and Drug Administration approval. Financial terms of the agreement were not disclosed.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight